Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jun 15:2009:2404.

Hodgkin's lymphoma

Amin Rahemtulla  1 , Evangelos Terpos
Affiliations

Hodgkin's lymphoma

Amin Rahemtulla et al. BMJ Clin Evid. .

Abstract

Introduction: People with Hodgkin's lymphoma usually present with a lump in the neck or upper chest, but a quarter of people also have fever, sweating, weight loss, fatigue, and itch. Almost all people with localised disease can be cured, and, even among people with relapsed advanced disease, almost 80% survive event free for 4 years or more.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of: single-regimen chemotherapy treatments; combined chemotherapy and radiotherapy treatments compared with radiotherapy alone; and combined chemotherapy and radiotherapy treatments compared with the same chemotherapy agent alone, for first presentation stage I or II non-bulky disease? What are the effects of: specific combined chemotherapy and radiotherapy treatments versus each other; or different radiotherapy treatment strategies in stage I or II non-bulky disease? What are the effects of: single-regimen chemotherapy treatments; dose-intensified chemotherapy treatments; or combined chemotherapy plus radiotherapy treatments compared with chemotherapy alone, for first presentation stage II (bulky) disease, III, or IV disease? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2008 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 40 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: ABVD (with or without radiotherapy); ABVPP plus radiotherapy; ChlVPP-EVA; COPP-ABVD plus radiotherapy; CVPP plus radiotherapy; EBVP plus radiotherapy; escalating-dose BEACOPP; extended-field radiotherapy; increased-dose regimens; involved-field radiotherapy; MOPP (with or without radiotherapy); MOPP-ABV plus radiotherapy; and VBM plus radiotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Herbertson R, Hancock BW. Hodgkin lymphoma in adolescents. Cancer Treat Rev 2005;31:339–360. - PubMed
    1. Thomas RK, Re D, Wolf J, et al. Part I: Hodgkin's lymphoma – molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004;5:11–18. - PubMed
    1. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002;55:162–176. - PMC - PubMed
    1. National Cancer Institute. Childhood Hodgkin's lymphoma (PDQ): treatment. Available online at: www.cancer.gov/cancertopics/pdq/treatment/childhodgkins. Last accessed 14 July 2010.
    1. Maclennan K, Vaughan Hudson B, Vaughan Hudson G. Histopathology: Hodgkin's disease. In: Hancock BW, Selby PJ, MacLennan K, et al, eds. Malignant lymphoma. London: Arnold Publishers, 2000,9–14.

Publication types